Home  >  News
Marketing + Font Resize -

Daiichi Sankyo introduces anticoagulant Lixiana OD tablets in Japan

Tokyo, Japan
Thursday, November 30, 2017, 11:00 Hrs  [IST]

Daiichi Sankyo Company has announced that it has launched its oral anticoagulant Lixiana OD tablets 15 mg, 30 mg and 60 mg (generic name: Edoxaban Tosilate Hydrate, date of manufacture and marketing approval: August 16, 2017; date of listing in NHI reimbursement price list in Japan: November 29, 2017) in Japan.

Lixianais a once daily oral anticoagulant that selectively, reversibly and directly inhibits FXa (activated blood coagulation factor X) which is involved in blood coagulation in blood vessels. Lixianahas the 3 indications of prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)], and prevention of VTE after major orthopedic surgery, and is currently widely used in the prevention and treatment of thromboembolism.

Daiichi Sankyo expects the addition of Lixiana OD Tablets, which are designed to be easy to take for elderly patients, to contribute greatly to increasing medication adherence* in patients requiring anticoagulant therapy.

Medication adherence: the extent to which patients actively follow a medication regimen as prescribed by their health care providers.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
Chemspec_India-2018
IPE_2018_Banner_150X60
InnoPack-Pharma_150x60_2018
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
IPX_Logo_2018_150x60_web
CPHI18_banner_150x6
CPhI_China_150x60-2018
CPhI_Japan_150x60_2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
duphat_150x60
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |